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A Mouse Model of Vitiligo with Focused Epidermal
Depigmentation Requires IFN-c for Autoreactive
CD8þ T-Cell Accumulation in the Skin
John E. Harris1, Tajie H. Harris2, Wolfgang Weninger3,4, E. John Wherry5, Christopher A. Hunter2
and Laurence A. Turka6
Vitiligo is an autoimmune disease of the skin causing disfiguring patchy depigmentation of the epidermis and,
less commonly, hair. Therapeutic options for vitiligo are limited, reflecting in part limited knowledge of disease
pathogenesis. Existing mouse models of vitiligo consist of hair depigmentation but lack prominent epidermal
involvement, which is the hallmark of human disease. They are thus unable to provide a platform to fully
investigate disease mechanisms and treatment. CD8þ T cells have been implicated in the pathogenesis of
vitiligo, and expression of IFN-g is increased in the lesional skin of patients, however, it is currently unknown
what role IFN-g has in disease. Here, we have developed an adoptive transfer mouse model of vitiligo using
melanocyte-specific CD8þ T cells, which recapitulates the human condition by inducing epidermal
depigmentation while sparing the hair. Like active lesions in human vitiligo, histology of depigmenting skin
reveals a patchy mononuclear infiltrate and single-cell infiltration of the epidermis. Depigmentation is
accompanied by accumulation of autoreactive CD8þ Tcells in the skin, quantifiable loss of tyrosinase transcript,
and local IFN-g production. Neutralization of IFN-g with antibody prevents CD8þ T-cell accumulation and
depigmentation, suggesting a therapeutic potential for this approach.
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INTRODUCTION
Vitiligo is a skin disease that causes patchy depigmentation of
the epidermis and afflicts B0.5% of the population, without
preference for race or gender. It commonly affects the central
face and genitals, often localizes to the hands and feet, and
less commonly presents on the trunk and proximal extremi-
ties (Taieb and Picardo, 2009). Hair pigmentation is often
spared within lesional skin, and the successful treatment of
vitiligo results in repigmentation that usually begins as small
dark macules around the hair follicles, presumably because
follicular melanocytes are protected by immune privilege
(Falabella, 2009).
Previous studies have implicated autoreactive CD8þ
T cells in disease pathogenesis. For example, the frequency
of anti-melanocyte CD8þ T cells in both the blood and skin
of patients with vitiligo correlate with the severity of disease,
and lesional CD8þ T cells induce melanocyte apoptosis in
unaffected skin ex vivo (Ogg et al., 1998; van den Boorn
et al., 2009), an observation that supports a direct role for
cytotoxic T lymphocytes in melanocyte destruction in human
vitiligo. The role of inflammatory cytokines is not yet fully
defined, although IFN-g has been the most extensively studied.
In human patients, IFN-g is expressed in lesional skin and can
be produced by autoreactive CD8þ T cells (van den Boorn
et al., 2009), but its role in depigmentation is not known.
Existing models of vitiligo have been established in wild-
type C57BL/6 mice, which have black hair but light skin
owing to the few melanocytes found in the epidermis.
Consequently, the majority of these models focus on
depigmentation of the hair rather than the epidermis, and
because hair depigmentation predicts a poor response to
treatment, they may represent more severe forms of vitiligo
(van den Boorn et al., 2009). Here, we report a mouse
model of vitiligo using adoptive transfer of melanocyte-
specific CD8þ T cells into mice with increased epidermal
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melanocytes, which results in black skin and black hair.
Similar to the common forms of human vitiligo, depigmenta-
tion in these mice affects the epidermis but spares the hair,
and the skin histologically resembles active human disease.
Mechanistic studies in this model reveal that depigmentation
requires IFN-g, which induces the local accumulation of
melanocyte-specific CD8þ T cells within the skin. These
results support a critical role for IFN-g in vitiligo and suggest
that it acts to recruit CD8þ T cells to the skin. The ability of
antibody-mediated neutralization of IFN-g to prevent CD8þ
T-cell accumulation in the skin as well as depigmentation in
this model suggests a therapeutic potential for this approach.
RESULTS
Vitiligo induction through the adoptive transfer of melanocyte-
specific CD8þ T cells consists of epidermal depigmentation
sparing the hair
To develop a mouse model of vitiligo with prominent
epidermal depigmentation, mice with black skin and hair
were used as hosts for the adoptive transfer of melanocyte-
specific CD8þ T cells. KRT14-Kitl*4XTG2Bjl (Krt14-Kitl*)
transgenic mice contain melanocytes in the epidermis owing
to the overexpression of Kit ligand (KITL) protein that is
noncleavable due to mutations in the proteolytic domains,
and is therefore membrane-bound (KITL*) (Majumdar et al.,
1994); expression is driven from the human keratin 14
promoter (Krt14), resulting in retention of melanocytes in the
epidermal basal layer and follicular epithelium. These mice
have black hair and black skin with an elevated number of
melanocytes in the epidermis but other cell populations are
normal, representative of human skin (Kunisada et al., 1998).
PMEL-specific TCR transgenic CD8þ T cells (PMEL CD8þ T
cells) recognize both mouse and human PMEL (also known as
gp100), a melanocyte-specific differentiation antigen (Over-
wijk et al., 1998). Using these cells, we modified a protocol
optimized for melanoma immunotherapy (Antony et al.,
2005) to induce vitiligo in our system. Naı¨ve CD8þ T cells
from the spleens of PMEL TCR transgenic mice were purified
by negative selection, and one million cells were transferred
intravenously into sublethally irradiated (500 rads) Krt14-Kitl*
hosts. To track PMEL CD8þ T cells after transfer, PMEL TCR
transgenic mice were crossed with mice that express green
fluorescent protein (GFP) driven by the DPE promoter, which
consists of the distal and proximal Cd4 enhancers and
promoter, but lacks a silencer element that prevents CD4
expression in mature CD8þ T cells; this results in GFP
expression in both CD4þ and CD8þ T cells (Mrass et al.,
2006). On the day of transfer, Krt14-Kitl* hosts were infected
intraperitoneally (i.p.) with 106 pfu of recombinant vaccinia
virus that expresses human PMEL (rVV-hPMEL), a potent
antigenic stimulus for PMEL CD8þ T cells that results in their
expansion in vivo (Overwijk et al., 2003). In summary, Krt14-
Kitl* hosts are sublethally irradiated, GFPþ PMEL CD8þ T cells
are adoptively transferred intravenously, and hosts are infected
i.p. with rVV-hPMEL to activate transferred T cells in vivo.
In all experiments, control mice were irradiated but
did not receive rVV-hPMEL or PMEL CD8þ T cells. In
preliminary experiments, when either irradiation or rVV-
hPMEL was eliminated from the protocol, depigmentation
occurred only inconsistently, and treatment with rVV-hPMEL
without PMEL CD8þ T-cell transfer did not result in
depigmentation (not shown). In all mice that received the
combination of sublethal irradiation, PMEL CD8þ T cells,
and rVV-hPMEL, epidermal depigmentation appeared 4–5
weeks after transfer. Depigmentation consistently involved
the ears, rear footpads, tail, and, less commonly, the nose;
occasionally, the trunk skin under the hair was affected
(Figure 1a), as well as the front footpads and genitals (not
shown). Depigmentation was initially patchy but often
progressed to confluence, involving the entire epidermal
surface, while depigmentation of the hair was not observed,
even months after transfer (Figure 1b). When wild-type
C57BL/6J mice with minimal epidermal pigment were used
as hosts, tail depigmentation occurred but the hair remained
unaffected (not shown). As in human vitiligo, there was no
evidence of skin inflammation, including redness, swelling,
or epidermal scale. While changes related to normal
physiology or aging of the Krt14-Kitl* mouse strain occasion-
ally included either mild lightening of the tail root or focal
depigmentation at the tip, the appearance was distinct from
the patchy depigmentation in mice with vitiligo.
The extent of depigmentation was objectively quantified
by an observer blinded to the treatment groups, using a point
scale based on the extent of depigmentation at four easily
visible locations, including the ears, nose, rear footpads, and
tail. Each location was examined and the extent of
depigmentation estimated as a percentage of the anatomic
site; both ears and both rear footpads were estimated together
and therefore evaluated as single sites. Points were
awarded according to the following scheme: no evidence
of depigmentation (0%) received a score of 0, 40–10%¼ 1
point, 410–25%¼ 2 points, 425–75%¼ 3 points,
475–o100%¼4 points, 100%¼5 points. The ‘‘vitiligo
score’’ was the sum of the scores at all four sites, with a
maximum score of 20 points. The vitiligo score of an
experimental group is reported as the average individual
score of each mouse within that group; a typical example
comparing control mice (irradiated only) and a group with
vitiligo is presented in Figure 1c.
Autoreactive T cells accumulate in the skin during vitiligo,
which correlates with melanocyte loss
Consistent with the hypothesis that vitiligo occurs following
skin infiltration of autoreactive T cells, PMEL CD8þ T cells
gradually accumulated in the ear skin of mice over the course
of disease. Total numbers of GFPþ (PMEL) T cells in the ear
skin were measured by flow cytometry. Accumulation
of these cells began 1–3 weeks after transfer, reached a
maximum at 5 weeks when depigmentation became evident,
and declined thereafter (Figure 2a). As expected, depletion of
CD8þ T cells 2 weeks after induction of vitiligo diminished
depigmentation (not shown). Other immune cell populations
commonly present in the skin were measured by flow
cytometry, and total numbers of bone marrow-derived cells
(CD45þ ), CD4þ T cells (CD4þ ), dendritic epidermal T cells
(CD3þgamma/deltaTCRþ ), total dendritic cells (CD11cþ ),
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langerinþ dendritic cells (langerinþCD11cþ ), and macro-
phages (MHCIIþ , CD11bþ and CD11c) were not statistically
different between lesional skin and controls (not shown).
In both mouse and human skin, melanocytes primarily
reside in the basal layer of the epidermis, a zone that forms a
narrow plane located just superficial to the dermal–epidermal
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Figure 1. Depigmentation targets the epidermis and spares the hair. (a) Within 4–5 weeks after treatment, hosts developed patchy depigmentation (arrows) at
visible epidermal surfaces, including the ears, nose, feet, tail, and occasionally on the trunk under the hair (photographed at 7 weeks). (b) Chronic vitiligo
resulted in widespread depigmentation of the epidermis but spared the hair (photographed at 18 weeks). (c) Mice with vitiligo were assigned a vitiligo score
based on the extent of involvement, and a representative result at 5 weeks is shown (error bars¼mean±SEM, n¼ 3 control, n¼ 5 vitiligo).
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junction. Hematoxylin and eosin (Hþ E)-stained sections of
lesional skin from affected mice 5 weeks after induction of
vitiligo revealed a patchy mononuclear infiltrate at the
dermal–epidermal junction where melanocytes reside, as
well as single-cell infiltration of the epidermis. The similarity
of these findings to human disease is illustrated by
comparison with histological sections from a patient with
vitiligo (Figure 2b), a presentation that is consistent with
previous reports (Ahn et al., 1994; Wankowicz-Kalinska
et al., 2003). Lastly, fresh, whole-mounted ears from mice
with vitiligo at 5 weeks after induction were visualized using
fluorescent microscopy, a technique that permits en face
examination of the distribution pattern of autoreactive GFPþ
PMEL CD8þ T cells across this plane. In areas of
macroscopically normal pigmentation, PMEL CD8þ T cells
within the ear were distributed both as single cells as well as
aggregated into distinct clusters (Figure 2c).
Melanocyte loss in lesional mouse ear skin was quantified
by measuring tyrosinase RNA expression in the whole ear at
regular times after induction of vitiligo. Tyrosinase expression
in each sample was first normalized to beta-actin (ACTB)
RNA transcript, and this result was divided by normalized
tyrosinase expression in control mice, representing the
fraction of remaining tyrosinase expression over the course
of vitiligo. When compared with control (irradiated only)
mice (0 weeks), expression slowly declined over the course of
disease, beginning soon after induction and becoming
significantly decreased by 60–70% after 5 weeks (Figure 3).
Similar results were observed using primers for PMEL (not
shown).
Depigmentation critically depends on IFN-c, as does
skin-specific accumulation of autoreactive CD8þ T cells
Consistent with human disease, IFN-g expression was
elevated within the depigmenting skin of mice with vitiligo,
and was expressed from autoreactive CD8þ T cells. This
expression, measured within the ear skin of mice using
quantitative real-time reverse transcriptase–PCR, was signifi-
cantly elevated starting 2 weeks after transfer and was
maintained throughout the course of disease (Figure 4a).
IFN-g expression in each sample was first normalized to
ACTB RNA transcript, and this result was divided by
normalized IFN-g expression in control mice (irradiated-
only), representing the fold induction of IFN-g over the course
of vitiligo. The expression of GFP from transferred PMEL
CD8þ T cells allowed the identification of the transferred
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Figure 3. Depigmentation correlates with loss of melanocytes. Ear skin from
affected mice was harvested at the indicated times. Quantitative real-time
reverse transcriptase–PCR revealed a quantifiable decrease in tyrosinase,
reflecting the progressive loss of melanocytes during disease (error
bars¼mean±SEM, n¼ 3 per time point).
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Figure 2. T cells accumulate in the skin during vitiligo. (a) Green fluorescent
protein (GFP)-labeled CD8þ T cells were quantified by flow cytometry of ear
skin at the indicated times (error bars¼mean±SEM, n¼ 3 per time point).
Example flow plots of the CD45þ gate are shown. (b) Tail skin from affected
mice harvested 5 weeks after transfer (mouse) is shown with affected skin
from a vitiligo patient (human), revealing a patchy mononuclear infiltrate at
the dermal–epidermal junction and epidermal infiltration (arrows). Normal
mouse skin is shown at inset, bars¼ 50mm. (c) Ears were harvested from mice
with vitiligo at 5 weeks after induction, and GFPþ T cells were visualized
with fluorescent microscopy (arrow). Bars¼100 mm. Hairs are visible as short,
linear yellow structures due to autofluorescence.
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population as distinct from endogenous CD8þ T cells using
flow cytometry. A proportion of PMEL CD8þ T cells from
skin-draining lymph nodes, but not endogenous T cells,
produced IFN-g following stimulation with their cognate
antigen human PMEL peptide, while both populations
produced IFN-g in response to stimulation with phorbol 12-
myristate 13-acetate and ionomycin (Figure 4b). ELISA assay
of cells from skin-draining lymph nodes confirmed secretion
of IFN-g protein following stimulation with human PMEL
peptide in mice with vitiligo but not controls, which included
stimulated cells from irradiated-only mice and unstimulated
cells from mice with vitiligo (not shown).
The expression of IFN-g correlates with depigmentation in
both human vitiligo and in this mouse model. In order to
determine if depigmentation requires IFN-g, vitiligo was
induced as before and host mice were treated either with
control antibody or IFN-g–neutralizing antibody (XMG-6) at a
dose of 100–500mg i.p. twice weekly. Initial studies revealed
that the administration of IFN-g–neutralizing antibody
beginning 1 day after vitiligo induction significantly inhibited
the development of depigmentation (not shown). In order to
rule out an effect on T-cell priming during rVV-hPMEL
infection, and to test whether IFN-g neutralization might be
useful as a treatment, IFN-g–neutralizing antibody treatment
was initiated 2 weeks after vitiligo induction. Even at this later
time point, the administration of IFN-g–neutralizing antibody
significantly abrogated depigmentation evaluated 5 weeks
after induction (Figure 5a), suggesting a specific effect on
autoimmunity. There was no difference in efficacy between
the two treatment schedules (not shown).
IFN-g has widely variable effects on the immune response,
including the polarization of T cells, upregulation of MHC I in
peripheral tissues, direct target cell cytotoxicity, the induction
of adhesion molecules on endothelial cells, and expression of
chemokines for homing to peripheral tissues (Marelli-Berg
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Figure 5. IFN-c neutralization prevents depigmentation and melanocyte-
specific CD8þ T-cell accumulation in the skin. IFN-g was neutralized
through intraperitoneal injection of IFN-g–neutralizing antibody (500mg)
beginning 2 weeks after induction and twice weekly until scored at 5 weeks
(error bars¼mean±SEM, n¼ 4 control, n¼5 vitiligo, n¼ 4 vitiligoþ IFN-g
blockade). (a) Vitiligo score is decreased by IFN-g neutralization. (b, c) The
effects of IFN-g–neutralizing antibody on the total numbers of melanocyte-
specific CD8þ T cells in the ear (b) and in skin-draining lymph nodes (c).
LN, lymph node.
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Figure 4. IFN-c expression is induced in the skin during vitiligo and is
produced by autoreactive CD8þ T cells. (a) Quantitative real-time reverse
transcriptase–PCR for IFN-g was performed on ear skin of mice at the
indicated times (error bars¼mean±SEM, n¼ 3 mice per time point).
(b) Single-cell suspensions were isolated from skin-draining lymph nodes 7
weeks after vitiligo induction and either left unstimulated, or stimulated with
PMEL peptide or phorbol 12-myristate 13-acetate (PMA) and ionomycin as
indicated. Following stimulation, cells were stained for IFN-g, and flow
cytometry revealed IFN-g expression in transferred melanocyte-specific
CD8þ T cells (green fluorescent protein-positive (GFPþ )) and endogenous
CD8þ T cells (GFP). Cells shown are gated on the total CD8þ population,
and the percentage shown is of either the total GFP or GFPþ gate.
A representative result is shown. Iono, ionomycin.
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and Jarmin, 2004; Andersen et al., 2006; Friedl and Weigelin,
2008). In order to determine whether autoreactive T-cell
numbers were directly affected by treatment with IFN-g
neutralization, total numbers of GFPþ (PMEL) T cells from
the skin and from skin-draining lymph nodes were quantified
using flow cytometry. The accumulation of PMEL CD8þ T
cells within ear skin was significantly diminished after IFN-g
neutralization (Figure 5b); however, the total numbers of
PMEL CD8þ T cells in skin-draining lymph nodes were
unaffected (Figure 5c), indicating that IFN-g is required
specifically for CD8þ T-cell accumulation in the skin, and
therefore may have a site-specific role in the development
of vitiligo.
DISCUSSION
This study describes, to our knowledge, a previously
unreported mouse model of vitiligo that targets the epidermis
but spares the hair. A recent study in humans with vitiligo
reported a direct correlation among the severity of vitiligo,
involvement of the hair, and autoreactive CD8þ T-cell
response to stimulation in vitro (van den Boorn et al., 2009).
Two other models of melanocyte-targeted immunity resulted
in prominent loss of the hair (Becker et al., 1996; Gilhar et al.,
2001); however, we do not observe this in our model. Studies
in a mouse model of melanoma immunotherapy report hair
depigmentation with a treatment protocol that includes PMEL
CD8þ T-cell adoptive transfer into RAG1/ hosts (Antony
et al., 2005), a result that we have reproduced (not shown).
These data demonstrate that melanocytes within the hair
follicle can serve as targets for PMEL CD8þ T cells under
certain immunological conditions, arguing against altered
PMEL antigen presentation by follicular melanocytes as a
cause for sparing of the hair in vitiligo. As the hair follicle is
an immune-privileged organ (Gilhar et al., 2007) and is often
protected from depigmentation in patients, the involvement
of the hair in existing mouse models of vitiligo suggests a
more robust T-cell response than the model presented here.
Thus, these models are complimentary, and may provide an
opportunity to further dissect the mechanisms of immune
tolerance in the hair follicle.
Flow cytometry of GFPþ T cells in the skin revealed that
autoreactive T cells accumulated gradually after transfer and
became maximal at 5 weeks. The loss of melanocytes
paralleled this accumulation, as levels decreased beginning
soon after transfer and continued for 5 weeks. These data
reveal an early loss of melanocytes before visible depigmen-
tation, suggesting subclinical disease induced by very few
infiltrating T cells. Fluorescence microscopy in our model
revealed microscopic clusters of T cells in areas of grossly
normal pigmentation, a pattern that is reminiscent of patchy
depigmentation but on a microscopic scale. A previous report
by Wankowicz-Kalinska et al. (2003) described the micro-
scopic infiltration of T cells in clinically normally pigmented
skin of patients with vitiligo, which was accompanied by
focal melanocyte loss by immunohistochemistry. They
labeled this phenomenon ‘‘microdepigmentation’’, and
hypothesized that it may represent the earliest stage in the
development of macroscopic depigmented lesions. Our data
describing the early accumulation and microscopic clustering
of autoreactive T cells in the skin with a quantifiable decrease
in melanocytes, all before macroscopic depigmentation,
support this concept.
Similar to human disease (van den Boorn et al., 2009), the
mouse model of vitiligo described here revealed that IFN-g
RNA transcript was elevated in affected skin and that
autoreactive CD8þ T cells produced IFN-g. Furthermore,
treatment with anti-IFN-g antibody abrogated depigmentation
in this model, which was associated with a prominent
deficiency in T-cell accumulation in the skin. Additional
studies including BrdU incorporation and staining for Ki-67
reveal limited evidence for proliferation within the skin (not
shown), suggesting that migration is a major component of
the T-cell accumulation during disease, and that IFN-g may
induce T-cell recruitment to the skin during vitiligo. A study
conducted by Gregg et al. (2010) reported that depigmenta-
tion of the hair and epidermis in their TCR transgenic mouse
model targeting tyrosinase was impaired in IFN-g/ mice,
consistent with our results. IFN-g–dependent mechanisms
related to T-cell homing to peripheral tissues include the
local induction of chemokines and the expression of
adhesion molecules on endothelial cells (Bromley et al.,
2008). Their studies identified a role for the chemokine
receptors CCR5 and CXCR3 in depigmentation. However,
their contribution, revealed using individual receptor-defi-
cient mice, was mild compared with IFN-g–deficient mice,
suggesting that additional IFN-g–dependent mechanisms
contributed to disease. Future studies will further define the
role of IFN-g in T-cell recruitment to the skin, and determine
whether IFN-g neutralization can reverse existing skin
depigmentation, which depends not only on inhibiting the
autoimmune response, but also on the ability of melanocytes
to repigment the epidermis.
The clinical significance of the treatment response to
IFN-g neutralization reported here lies in its potential use as a
new therapy for vitiligo. However, this must be balanced with
the understanding that IFN-g is required for clearance of
a number of pathogens (Zhang et al., 2008), and thus future
studies to implicate critical events downstream of IFN-g
signaling may provide more targeted, and therefore safer,
systemic treatments for vitiligo and related autoimmune
diseases. In addition to testing systemic treatments for vitiligo,
future studies will take advantage of the prominent epidermal
depigmentation observed in this model of vitiligo to test new
topical treatments.
MATERIALS AND METHODS
Mice
KRT14-Kitl*4XTG2Bjl (Krt14-Kitl*) mice were a gift from BJ Longley,
University of Wisconsin. GFP-PMEL TCR transgenic mice were
produced by crossing DPEGFP mice that express GFP in T cells
(provided by U von Andrian, Harvard Medical School, Boston, MA)
with the PMEL TCR transgenic mouse strain (The Jackson Laboratory,
Bar Harbor, ME, stock no. 005023, B6.Cg-Thy1a/CyTg(TcraTcrb)8R-
est/J). All mice were on a C57BL/6J background, were maintained in
pathogen-free facilities (monitored regularly for the pathogens listed
in the HM Plus panel, Charles River Laboratories, Wilmington, MA)
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at the University of Pennsylvania, and procedures were approved by
the University of Pennsylvania Institutional Animal Care and Use
Committee.
Induction of vitiligo through adoptive transfer of purified PMEL
CD8þ T cells
GFP-PMEL CD8þ T cells were isolated from the spleen of GFP-PMEL
TCR transgenic mice through negative selection on microbeads
(Miltenyi Biotech, Auburn, CA) according to the manufacturer’s
instructions. Purified CD8þ T cells (1 106) were injected
intravenously into sublethally irradiated (500 rads 1 day before
transfer) Krt14-Kitl* hosts (12–16 weeks of age). Recipient mice also
received i.p. injection of 1 106 pfu rVV-hPMEL (N Restifo, NCI,
NIH, UK) on the same day of transfer. IFN-g blockade was through
i.p. injection of 100–500 mg of IFN-g–neutralizing antibody (XMG-6)
beginning at the indicated times and twice weekly for the duration of
the observation period (5–7 weeks). Mice used as controls for vitiligo
were sublethally irradiated but did not receive rVV-hPMEL or PMEL
CD8þ T-cell transfer. Mice with vitiligo used as treatment controls
for IFN-g blockade were treated with either no antibody or with an
equal quantity of Rat IgG.
Flow cytometry
Ears and lymph nodes were harvested at the indicated times. The
protocol to obtain single-cell suspensions of ear skin was modified
from Suffia et al. (2005). The ventral and dorsal sheets of the ears
were separated and deposited dermal side down in the skin digest
media (RPMI containing 0.5% DNase I (Sigma-Aldrich, St Louis,
MO) and 0.5 mg ml1 of liberase CI enzyme blend (Roche,
Indianapolis, IN)), and were incubated for 90 minutes at 371C. The
sheets were dissociated in skin digest media plus 3% serum and
5 mM EDTA using a medimachine (BD Biosciences, San Jose, CA)
according to the manufacturer’s instructions, and filtered using a 70-
mm cell strainer. For the analysis of intracellular cytokines, single-
cell suspensions from the lymph nodes were stimulated with 1 mM
soluble hPMEL2533 peptide or phorbol 12-myristate 13-acetate
(50 ng ml1) and ionomycin (500 ng ml1) in the presence of
brefeldin A (10 mg ml1) for 5 h at 371C with 5% CO2. The cells
were incubated with Fc block in PBS containing 0.1% BSA, 1 mM
EDTA, and then stained for the surface markers CD8b (YTS156.7.7,
phycoerythrin-labeled) and CD45.2 (104, APC-efluor780-labeled) as
well as Live/Dead Aqua fixable viability dye (Invitrogen, Carlsbad,
CA). When indicated, the cells were then fixed, permeabilized, and
stained for the cytokine IFN-g (XMG1.2, PerCP-Cy5.5-labeled).
Incubations were performed for 30 minutes on ice. For each ear, the
entire suspension was analyzed. The total number of CD8bþ GFPþ
cells per ear was calculated by gating on live, CD45.2þ , CD8bþ ,
and GFPþ cells, and reported as total number of CD8bþGFPþ cells
per total number of CD45.2þ cells. The frequency of IFN-g
producers was determined by gating on live, CD8bþ cells, setting
a GFPþ gate and reporting the frequency as a percentage of total
GFPþ (transferred) or GFP (endogenous) cells. For each lymph
node sample, at least 100,000 cells were analyzed and the total
number of GFPþ cells was calculated by dividing the GFPþ count
by the singlet count and then multiplying by the total number of
lymph node cells. The data were collected and analyzed using
CELLQuestTM software and a FACSCaliburTM flow cytometer (BD
Biosciences).
Microscopy
For microscopic examination of affected skin, mouse tails were
excised and fixed in 10% neutral-buffered formalin. Tissues were
embedded in paraffin, sectioned, and stained with Hþ E. For human
samples, 8–10-mm formalin-fixed, paraffin-embedded biopsy speci-
mens were obtained from the Penn Skin Disease Research Center
Tissue Bank (Philadelphia, PA). De-identified samples were obtained
from a patient with a vitiligo diagnosis and a T-cell infiltrate.
Sections were stained with Hþ E according to standard procedures.
For fluorescence microscopy of fresh tissue, ears were harvested,
depilated, split into anterior and posterior halves, mounted on a glass
slide with PBS and visualized on a fluorescent microscope. All
images were captured on a Nikon Eclipse E600 microscope (Nikon,
Melville, NY) equipped with a Photometrics Cool Snap EZ CCD
camera for fluorescent images (Photometrics, Tucson, AZ), or a
Nikon DS-Fi1 camera for light microscopy (Nikon), using Nikon NIS
Elements software.
Quantitative real-time reverse transcriptase–PCR
Ears were minced into o5 mm strips, stored in RNAlater (Ambion,
Austin, TX) overnight at 41C and then transferred to 201C until RNA
was extracted using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Complementary DNA
was generated using Superscript II reverse transcriptase (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions, and real-
time PCR was performed using primers for murine IFN-g (previously
described in Elso et al. (2004)) or murine tyrosinase (Applied
Biosystems, Carlsbad, CA), and normalized to ACTB RNA transcript
(Qiagen, Germantown, MD). Real-time PCR was performed using
either 2 Power SYBR Green PCR master mix (for IFN-g and ACTB)
or Taqman 2 PCR master mix (for tyrosinase) on a 7500 Fast Real
time PCR system (Applied Biosystems) according to the manufac-
turer’s instructions. Gene expression is reported relative to
the average expression at time 0 after normalization to expression
of ACTB.
Statistical analysis
Statistical analysis was performed using Prism software (GraphPad
Software, La Jolla, CA). Dual comparisons were made using the
unpaired Student’s t-test, and longitudinal comparison determined
using linear regression.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We would like to thank Mohammed Ali for excellent technical assistance. The
Penn Skin Disease Research Center Core was responsible for identification
and processing of human tissue samples, and was funded by NIH grant 5-P30-
AR057217-03. This project was supported by NIH grants AI041521 (to LAT)
and AI071302 (to CAH). JEH was supported by NIH training grant T32-
AR007465 and research grants from the La Roche-Posay Research Founda-
tion, AMBI Research Foundation/Skin of Color Society, and the Dermatology
Foundation.
REFERENCES
Ahn SK, Choi EH, Lee SH et al. (1994) Immunohistochemical studies from
vitiligo—comparison between active and inactive lesions. Yonsei Med J
35:404–10
www.jidonline.org 1875
JE Harris et al.
IFN-g in Vitiligo Recruits T Cells to the Skin
Andersen MH, Schrama D, Thor Straten P et al. (2006) Cytotoxic T cells. J
Invest Dermatol 126:32–41
Antony PA, Piccirillo CA, Akpinarli A et al. (2005) CD8+ T cell immunity
against a tumor/self-antigen is augmented by CD4+ T helper cells and
hindered by naturally occurring T regulatory cells. J Immunol
174:2591–601
Becker JC, Varki N, Brocker EB et al. (1996) Lymphocyte-mediated alopecia
in C57BL/6 mice following successful immunotherapy for melanoma.
J Invest Dermatol 107:627–32
Bromley SK, Mempel TR, Luster AD (2008) Orchestrating the orchestrators:
chemokines in control of T cell traffic. Nat Immunol 9:970–80
Elso CM, Roberts LJ, Smyth GK et al. (2004) Leishmaniasis host response loci
(lmr1-3) modify disease severity through a Th1/Th2-independent path-
way. Genes Immun 5:93–100
Falabella R (2009) Vitiligo and the melanocyte reservoir. Indian J Dermatol
54:313–8
Friedl P, Weigelin B (2008) Interstitial leukocyte migration and immune
function. Nat Immunol 9:960–9
Gilhar A, Landau M, Assy B et al. (2001) Melanocyte-associated T cell
epitopes can function as autoantigens for transfer of alopecia areata to
human scalp explants on Prkdc(scid) mice. J Invest Dermatol 117:1357–62
Gilhar A, Paus R, Kalish RS (2007) Lymphocytes, neuropeptides, and genes
involved in alopecia areata. J Clin Invest 117:2019–27
Gregg RK, Nichols L, Chen Y et al. (2010) Mechanisms of spatial and
temporal development of autoimmune vitiligo in tyrosinase-specific TCR
transgenic mice. J Immunol 184:1909–17
Kunisada T, Lu SZ, Yoshida H et al. (1998) Murine cutaneous mastocytosis
and epidermal melanocytosis induced by keratinocyte expression of
transgenic stem cell factor. J Exp Med 187:1565–73
Majumdar MK, Feng L, Medlock E et al. (1994) Identification and mutation of
primary and secondary proteolytic cleavage sites in murine stem cell
factor cDNA yields biologically active, cell-associated protein. J Biol
Chem 269:1237–42
Marelli-Berg FM, Jarmin SJ (2004) Antigen presentation by the endothelium: a
green light for antigen-specific T cell trafficking? Immunol Lett
93:109–13
Mrass P, Takano H, Ng LG et al. (2006) Random migration precedes stable
target cell interactions of tumor-infiltrating T cells. J Exp Med
203:2749–61
Ogg GS, Rod Dunbar P, Romero P et al. (1998) High frequency of skin-
homing melanocyte-specific cytotoxic T lymphocytes in autoimmune
vitiligo. J Exp Med 188:1203–8
Overwijk WW, Theoret MR, Finkelstein SE et al. (2003) Tumor regression and
autoimmunity after reversal of a functionally tolerant state of self-reactive
CD8+ T cells. J Exp Med 198:569–80
Overwijk WW, Tsung A, Irvine KR et al. (1998) gp100/pmel 17 is a murine
tumor rejection antigen: induction of ‘self’-reactive, tumoricidal T cells
using high-affinity, altered peptide ligand. J Exp Med 188:277–86
Suffia I, Reckling SK, Salay G et al. (2005) A role for CD103 in the retention of
CD4+CD25+ Treg and control of Leishmania major infection. J Immunol
174:5444–55
Taieb A, Picardo M (2009) Clinical practice. Vitiligo. N Engl J Med 360:160–9
van den Boorn JG, Konijnenberg D, Dellemijn TA et al. (2009) Autoimmune
destruction of skin melanocytes by perilesional T cells from vitiligo
patients. J Invest Dermatol 129:2220–32
Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ et al. (2003)
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is
associated with melanocyte loss in human vitiligo. Lab Invest 83:683–95
Zhang SY, Boisson-Dupuis S, Chapgier A et al. (2008) Inborn errors of
interferon (IFN)-mediated immunity in humans: insights into the
respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host
defense. Immunol Rev 226:29–40
1876 Journal of Investigative Dermatology (2012), Volume 132
JE Harris et al.
IFN-g in Vitiligo Recruits T Cells to the Skin
